best glutathione for sale Doctor's + Milk Thistle Supplement - Supports Liver Health & Antioxidant Activity Women & Men, Comprehensive Formula, Non-GMO, Gluten Free, Soy Free, Vegan Anna Magkawas Nature's Bounty Vitamin B-12 Size:100 Box
Nature's Bounty Vitamin B-12 2500 mcg, 300 Quick Dissolve Tablets
Back to Journals » Psoriasis: Targets and Therapy » Volume 15 » default Psoriasis: Targets and Therapy View all (225) Volume 16, 2026 (21) Volume 15, 2025 (48) Volume 14, 2024 (23) Volume 13, 2023 (7) Volume 12, 2022 (22) Volume 11, 2021 (14) Volume 10, 2020 (8) Volume 9, 2019 (13) Volume 8, 2018 (12) Volume 7, 2017 (9) Volume 6, 2016 (15) Volume 5, 2015 (13) Volume 4, 2014 (5) Volume 3, 2013 (4) Volume 2, 2012 (10) Volume 1, 2011 (1) Archive: Volume 15, 2025 Real-World Experience of Guselkumab in the Elderly Population Fratton Z, Bighetti S, Bettolini L, Maione V, Rossi M, Venturini M, Mazzoletti V, Zelin E, Stinco G, Errichetti E Psoriasis: Targets and Therapy 2025, 15:581-601 Published Date: 26 December 2025 Global Trends and Future Predictions of Psoriasis Burden: Insights from the GBD 2021 Study Gu X, Wang X, Bin Y, Xue R, Zhu G Psoriasis: Targets and Therapy 2025, 15:569-580 Published Date: 24 December 2025 Antibodies Targeting Gasdermin E as a Potential Therapeutic Option for Psoriasis – A Pilot Study on a Mouse Model Nowowiejska-Purpurowicz J, Hermanowicz JM, Pawlak D, Flisiak I, Lipinski T Psoriasis: Targets and Therapy 2025, 15:561-567 Published Date: 18 December 2025 PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study Chen YF, Jiang YS, Chen YC, Chang CH, Jan JS Psoriasis: Targets and Therapy 2025, 15:545-559 Published Date: 29 November 2025 Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis Liu J, Fan H, Sun R, Pang Y, Li X, Ma Q, Xu C, Zhang D, Ma W Psoriasis: Targets and Therapy 2025, 15:535-543 Published Date: 31 October 2025 Predictors of Successful Secukinumab Dose Tapering in Moderate-to-Severe Psoriasis: A Retrospective Study Chen J, Xiao Z, Zeng X, Xiang N, Luo R, Chen R, Lin B, Ke H, Gong T, Ji C Psoriasis: Targets and Therapy 2025, 15:527-534 Published Date: 17 October 2025 Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis Dai M, Jiang Y, Xi Y, Xu L, Huang D, Wang Y, Hu Y, Yu Q, Shi Y Psoriasis: Targets and Therapy 2025, 15:513-525 Published Date: 13 October 2025 Integrated Single-Cell RNA Sequencing and Proteome-Wide Mendelian Randomization Identifies Therapeutic Targets for Psoriasis and Associated Complications Zheng P, Cao Y, Wang A, Yi K Psoriasis: Targets and Therapy 2025, 15:501-511 Published Date: 10 October 2025 Codon-Usage Bias and Genomic Architecture of 79 Psoriasis-Susceptibility Genes: Implications for Expression Efficiency and Therapeutic Targeting Jiang S, Chen L, Li J, Gao F, Yan X, Zhao Y Psoriasis: Targets and Therapy 2025, 15:479-499 Published Date: 25 September 2025 Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review Yao Y, Ma Y, Zhong H, Guo F, Zhu J, Wu Y, Tang S Psoriasis: Targets and Therapy 2025, 15:471-478 Published Date: 23 September 2025 Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, Bernardini N, Balato A, Campanati A, Esposito M, Bonifati C, Lora V, Potestio L, Lembo S, Loconsole F, De Luca E, Skroza N, Buononato D, Bianchelli T, Fargnoli MC, Tommasino N, Foti C, De Simone C, Bianchi L, Galluzzo M Psoriasis: Targets and Therapy 2025, 15:455-469 Published Date: 16 September 2025 Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023 Zhang M, Chen JL, Fan SW, Sun XY, Zhou YQ, Luo Y, Wang J, Wang CX, Lin NX, Liu L, Li X Psoriasis: Targets and Therapy 2025, 15:443-453 Published Date: 27 August 2025 Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis Peng L, Wang L, Chen L, Shen Z Psoriasis: Targets and Therapy 2025, 15:429-442 Published Date: 21 August 2025 The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome Tang L, Bi H, Lin K, Chen Y, Xian H, Li Y, Xie H, Zheng G, Wang P, Chen Y, Yang B, Tan Y, Song Q, Wang M, Li G, Chang J, Guan Y, So KF, Lu C Psoriasis: Targets and Therapy 2025, 15:411-428 Published Date: 18 August 2025 Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis Gisondi P, Bellinato F, Curic T, Girolomoni G Psoriasis: Targets and Therapy 2025, 15:401-410 Published Date: 18 August 2025 Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study Yao L, Wang X, Lu D, Tian S Psoriasis: Targets and Therapy 2025, 15:389-399 Published Date: 16 August 2025 Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort Ma X, Xu Q, Kuai L, Shen F, Duan Z, Gao X, Zhang R, Wang R Psoriasis: Targets and Therapy 2025, 15:373-387 Published Date: 13 August 2025 TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses Dai B, Tang Y, Zhang B, Xu G, Zhang Y, Ze K Psoriasis: Targets and Therapy 2025, 15:361-372 Published Date: 12 August 2025 Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis – A Comprehensive Literature Review Al Alshaikh SA, Almarhoon ZM, Momattin H, Aleid M, Almousa ZH, Alqaisum AK, Mobarki FI, Almakki SA, Alturfi H, Almajed KJ Psoriasis: Targets and Therapy 2025, 15:351-360 Published Date: 5 August 2025 Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years Mastorino L, Dapavo P, Burlando M, Gisondi P, Maronese CA, Ruggiero A, Galluzzo M, Pisani MC, Sacchelli L, Caldarola G, Avallone G, Marzano AV, Megna M, Campione E, Loconsole F, Bardazzi F, De Simone C, Quaglino P, Ribero S Psoriasis: Targets and Therapy 2025, 15:339-350 Published Date: 4 August 2025 Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment – Large-Scale Claims Data Analysis Wagner JN, Hagenström K, Müller KS, Stephan B, Augustin M, von Kiedrowski R Psoriasis: Targets and Therapy 2025, 15:327-338 Published Date: 5 August 2025 Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis Xiao Y, Sun J Psoriasis: Targets and Therapy 2025, 15:321-325 Published Date: 23 July 2025 Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach Xu JM, Wu C, Feng H, Jin HZ Psoriasis: Targets and Therapy 2025, 15:301-320 Published Date: 19 July 2025 Psoriasis Does Not Seem to Impair Glomerular and Tubular Function – The Comprehensive Study on Serum and Urine Nowowiejska J, Baran A, Hermanowicz JM, Sieklucka B, Koper-Lenkiewicz OM, Kamińska J, Pawlak K, Pawlak D, Flisiak I Psoriasis: Targets and Therapy 2025, 15:285-299 Published Date: 18 July 2025 Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany – Methodology and Outcomes of Claims Data Analysis Hagenström K, Müller K, Ben-Anaya N, Augustin M Psoriasis: Targets and Therapy 2025, 15:273-283 Published Date: 15 July 2025 Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study Shen F, Ding Y, Qiang Y, Duan Z, Xu Q, Gao X, Zhang R, Wang R Psoriasis: Targets and Therapy 2025, 15:261-272 Published Date: 14 July 2025 Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M Psoriasis: Targets and Therapy 2025, 15:243-259 Published Date: 28 June 2025 Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience Bertoli C, Torres T, Romita P, Stingeni L, Hansel K, Mastorino L, Ortoncelli M, Panzone M, Cruz MJ, Bianchi L, Zangrilli A, Musumeci ML, Micali G, Gerbino C, Simonetti O, De Simoni E, Longo C, Mahé E, Di Lernia V Psoriasis: Targets and Therapy 2025, 15:233-241 Published Date: 28 June 2025 Evolution of Drug Supply for Psoriasis from 2010 to 2022 – Real-World Claims Data Analysis in Germany Hagenström K, Klinger T, Stephan B, Augustin M Psoriasis: Targets and Therapy 2025, 15:221-231 Published Date: 27 June 2025 Acupoint Injection Combined with BCG-PSN and Thymosin Enteric-Coated Tablets Improve China Han Psoriasis Vulgaris by Regulating T Cell Subsets Li J, Zhao X, Pan H, Duan Y, Li W, Zhao Y, Yao L, Zhang K Psoriasis: Targets and Therapy 2025, 15:209-220 Published Date: 19 June 2025 Are Systemic Drug Choices for Psoriasis by Dermatologists Compatible with Psoriatic Arthritis
Anna Magkawas
Size:100 Box
[DOI] [PubMed] 6.Smit AA, Halliwill JR, Low PA, Wieling W
)
